Genmab aktie (GMAB) | Pressmeddelande

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GlobeNewswire • 21 Nov 20:48

Genmab Announces Financial Results for the First Nine Months of 2024

GlobeNewswire • 06 Nov 17:02

Genmab to Present at Jefferies London Healthcare Conference

GlobeNewswire • 05 Nov 19:11

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) A...

GlobeNewswire • 05 Nov 18:00

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

GlobeNewswire • 15 Oct 12:25

Major Shareholder Announcement

GlobeNewswire • 04 Oct 19:55

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GlobeNewswire • 26 Sep 21:17

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovaria...

GlobeNewswire • 15 Sep 14:45

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 10 Sep 22:06

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire • 26 Aug 18:26

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphom...

GlobeNewswire • 19 Aug 20:00

Genmab Announces Changes to its Executive Committee

GlobeNewswire • 16 Aug 15:00

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 13 Aug 20:53

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 13 Aug 20:51

Genmab Announces Financial Results for the First Half of 2024

GlobeNewswire • 08 Aug 17:03

Genmab Updates 2024 Financial Guidance

GlobeNewswire • 08 Aug 17:00

Genmab Takes Full Control of Acasunlimab Development Program

GlobeNewswire • 05 Aug 11:50

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024

GlobeNewswire • 17 Jul 12:25

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

GlobeNewswire • 28 Jun 08:00

Completion of Share Buy-back Program

GlobeNewswire • 27 Jun 23:00

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

GlobeNewswire • 27 Jun 01:03

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 24 Jun 15:55

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 18 Jun 20:45

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 17 Jun 15:33

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GlobeNewswire • 12 Jun 21:45

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 11 Jun 20:50

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 10 Jun 16:18

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire • 05 Jun 18:51

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 03 Jun 15:09

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and...

GlobeNewswire • 03 Jun 15:00

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate i...

GlobeNewswire • 02 Jun 23:30

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 T...

GlobeNewswire • 01 Jun 16:00

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 27 May 16:16

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire • 23 May 23:00

Genmab Completes Acquisition of ProfoundBio

GlobeNewswire • 21 May 17:06

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 21 May 13:19

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 202...

GlobeNewswire • 14 May 16:02

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 13 May 16:09

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 07 May 20:27

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 06 May 16:01

Genmab Announces Financial Results for the First Quarter of 2024

GlobeNewswire • 02 May 17:01

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

GlobeNewswire • 30 Apr 00:40

Transactions in Connection with Share Buy-back Program Genmab

GlobeNewswire • 29 Apr 10:24

Transactions in Connection with Share Buy-back Program Genmab

GlobeNewswire • 22 Apr 09:30

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

GlobeNewswire • 16 Apr 12:24

Transactions in Connection with Share Buy-back Program Genmab

GlobeNewswire • 15 Apr 10:07

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 08 Apr 11:44

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

GlobeNewswire • 03 Apr 07:34

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 02 Apr 09:24

Transactions in Connection with Share Buy-back Program

GlobeNewswire • 25 Mar 14:31

Completion of share buy-back program

GlobeNewswire • 18 Mar 10:49

Genmab Announces Initiation of Share Buy-Back Program

GlobeNewswire • 15 Mar 13:16

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 13 Mar 21:58

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants t...

GlobeNewswire • 13 Mar 21:53

Passing of Genmab A/S’ Annual General Meeting

GlobeNewswire • 13 Mar 16:13

Transactions in connection with share buy-back program

GlobeNewswire • 11 Mar 10:42

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 04 Mar 19:10

Transactions in connection with share buy-back program

GlobeNewswire • 04 Mar 10:29

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 02 Mar 00:04

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 29 Feb 16:48

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 27 Feb 21:42

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 27 Feb 21:40

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relaps...

GlobeNewswire • 27 Feb 01:45

Transactions in connection with share buy-back program

GlobeNewswire • 26 Feb 11:21

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 23 Feb 23:50

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

GlobeNewswire • 23 Feb 23:35

Transactions in connection with share buy-back program

GlobeNewswire • 19 Feb 10:40

Notice to Convene the Annual General Meeting of Genmab A/S

GlobeNewswire • 15 Feb 12:00

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

GlobeNewswire • 14 Feb 20:09

Genmab Announces Initiation of Share Buy-Back Program

GlobeNewswire • 14 Feb 17:41

Genmab Publishes 2023 Annual Report

GlobeNewswire • 14 Feb 17:02

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervic...

GlobeNewswire • 02 Feb 12:45

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GlobeNewswire • 25 Jan 20:22

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023

GlobeNewswire • 23 Jan 12:24

Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen

GlobeNewswire • 23 Jan 00:40

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.

GlobeNewswire • 09 Jan 12:45

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

GlobeNewswire • 03 Jan 06:55

Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire • 02 Jan 15:52

Genmab to Hold 2023 R&D Update and ASH Data Review Meeting

GlobeNewswire • 12 Dec 2023 13:00

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with H...

GlobeNewswire • 09 Dec 2023 18:00

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 05 Dec 2023 23:26

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lympho...

GlobeNewswire • 27 Nov 2023 13:00

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GlobeNewswire • 21 Nov 2023 22:45

Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

GlobeNewswire • 21 Nov 2023 22:42

Major Shareholder Announcement

GlobeNewswire • 09 Nov 2023 15:14

Genmab to Present at Jefferies London Healthcare Conference

GlobeNewswire • 09 Nov 2023 11:00

Major Shareholder Announcement

GlobeNewswire • 08 Nov 2023 17:09

Genmab Announces Financial Results for the First Nine Months of 2023

GlobeNewswire • 07 Nov 2023 17:01

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

GlobeNewswire • 02 Nov 2023 14:05

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared ...

GlobeNewswire • 22 Oct 2023 16:30

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023

GlobeNewswire • 17 Oct 2023 12:22

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GlobeNewswire • 28 Sep 2023 20:38

Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell L...

GlobeNewswire • 25 Sep 2023 13:45

EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients w...

GlobeNewswire • 25 Sep 2023 11:55

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 12 Sep 2023 20:04

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recu...

GlobeNewswire • 04 Sep 2023 21:00

Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference

GlobeNewswire • 28 Aug 2023 16:06

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire • 15 Aug 2023 19:09

Genmab Announces Financial Results for the First Half of 2023

GlobeNewswire • 03 Aug 2023 17:01

Genmab Updates 2023 Financial Guidance

GlobeNewswire • 28 Jul 2023 00:01

Börskollen

För dig med koll på börsen

Pressmeddelanden från Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Announces Financial Results for the First Nine Months of 2024

Genmab to Present at Jefferies London Healthcare Conference

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Major Shareholder Announcement

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab Announces Changes to its Executive Committee

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab Announces Financial Results for the First Half of 2024

Genmab Updates 2024 Financial Guidance

Genmab Takes Full Control of Acasunlimab Development Program

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Completion of Share Buy-back Program

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Transactions in Connection with Share Buy-back Program

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions in Connection with Share Buy-back Program

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

Transactions in Connection with Share Buy-back Program

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Transactions in Connection with Share Buy-back Program

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab Completes Acquisition of ProfoundBio

Transactions in Connection with Share Buy-back Program

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Transactions in Connection with Share Buy-back Program

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program

Genmab Announces Financial Results for the First Quarter of 2024

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Transactions in Connection with Share Buy-back Program Genmab

Transactions in Connection with Share Buy-back Program Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

Transactions in Connection with Share Buy-back Program Genmab

Transactions in Connection with Share Buy-back Program

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program

Completion of share buy-back program

Genmab Announces Initiation of Share Buy-Back Program

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Passing of Genmab A/S’ Annual General Meeting

Transactions in connection with share buy-back program

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions in connection with share buy-back program

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Capital Increase in Genmab as a Result of Employee Warrant Exercise

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

Transactions in connection with share buy-back program

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Transactions in connection with share buy-back program

Notice to Convene the Annual General Meeting of Genmab A/S

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Genmab Announces Initiation of Share Buy-Back Program

Genmab Publishes 2023 Annual Report

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023

Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons